Evidence map›Paper›PMID 38187608›Full record

ArticlebioRxiv : the preprint server for biology2025

Attenuating ABHD17 isoforms augments the

Charneal L Dixon, Noah R Martin, Micah J Niphakis, Benjamin F Cravatt, Gregory D Fairn

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Charneal L DixonDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Noah R MartinDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Micah J NiphakisLundbeck La Jolla Research Center, Inc., San Diego, CA, USA.
Benjamin F CravattDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.
Gregory D FairnDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.ORCID 0000-0001-6508-168X
St. Michael's Hospital · CADalhousie University · CALa Jolla Alcohol Research · USScripps Research Institute · US

Funding

Selectively Targeting Oncogenic NRAS in CancerR01CA193994 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEVIN M. SHANNON · 2015 to 2026
$5.8M
NCI NIH HHS R01 CA193994
6 · The paper itself

Abstract

BACKGROUND AND

aimsNOD2 is an intracellular innate immune receptor that detects bacterial peptidoglycan fragments. Although nominally soluble, some NOD2 is associated with the plasma membrane and endosomal compartments for microbial surveillance. This membrane targeting is achieved through post-translational

methodsTo identify the enzymes responsible for NOD2 deacylation, we used engineered cell lines with RNA interference and small-molecule inhibitors. These approaches were combined with confocal microscopy, acyl-resin-assisted capture, immunoblotting, and cytokine multiplex assays.

resultsWe identified

conclusionsThese findings demonstrate that ABHD17 isoforms are negative regulators of NOD2. The results also suggest that targeting ABHD17 isoforms could restore functionality to specific Crohn's disease-associated NOD2 variants, offering a potential therapeutic strategy.

Indexed as

ABHD17Acyl Protein ThioesteraseCrohn’s diseaseIL-8InflammationNOD2S-acylation

Identifiers

PMID38187608
PMCPMC10769251
OpenAlexW4390080811

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.